LDN-193189 (hydrochloride)

LDN-193189 inhibits SMAD1/5/8 phosphorylation by the bone morphogenetic protein (BMP) type I receptors, which are known as activin receptor-like kinases (ALKs), with an IC50 value of 4.9 nM. In in vitro kinase assays, it shows specificity for ALK1, 2, 3, and 6 (IC50s = 0.8, 0.8, 5.3, and 16.7 nM, respectively) over ALK4 and 5 (IC50s = 101 and 350 nM, respectively). LDN-193189 has been used to inhibit BMP type I receptor activity to study the pathogenesis of fibrodysplasia ossificans progressive, a congenital hyperossification disorder, and to examine the role of osteogenesis in prostate tumor metastases in bone.Formal Name: 4-[6-[4-(1-piperazinyl)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]-quinoline, dihydrochloride. CAS Number: 1435934-00-1. Synonyms: DM-3189. Molecular Formula: C25H22N6 . 2HCl. Formula Weight: 479.4. Purity: >98%. Formulation: (Request formulation change), A crystalline solid. Solubility: DMF: 1 mg/ml, DMSO: 2 mg/ml. lambdamax: 235, 290, 387 nm. SMILES: N1(C2=CC=C(C(C=N3)=CN4C3=C(C5=CC=NC6=C5C=CC=C6)C=N4)C=C2)CCNCC1.Cl.Cl. InChi Code: InChI=1S/C25H22N6.2ClH/c1-2-4-24-22(3-1)21(9-10-27-24)23-16-29-31-17-19(15-28-25(23)31)18-5-7-20(8-6-18)30-13-11-26-12-14-30,,/h1-10,15-17,26H,11-14H2,2*1H. InChi Key: CMQXLLAILGGLRV-UHFFFAOYSA-N.